Summary: In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor–resistant breast cancers. See related article by Dietrich et al., p. 446 (8).

中文翻译：

---

备受期待的 CDK2 选择性治疗剂：INX-315

摘要：在本期中，Dietrich、Trub 及其同事描述并表征了一种新型选择性 CDK2 抑制剂：INX-315。该药物在 CCNE1 扩增的癌症和 CDK4/6 抑制剂耐药的乳腺癌中显示出前景。请参阅 Dietrich 等人的相关文章，第 17 页。446（8）。